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A CONTROLLED TRIAL OF GLIFANAN AND OMNOPON IN POSTOPERATIVE PAIN*
D. M. LITHGOW, B.Sc., M.B., B.CH. (RAND), F.R.C.S. (EDIN.) AND J. BLECHER, B.Sc., M.D. (RAND), M.R.C.O.G.,
F.e.o.G. (S.A.), Department oj Obstetrics and Gynaecology, University oj the Witwatersrand, Johannesburg
*These operations included 34 salpingectomies, 3 salpingo-oophorectomies.
4 ovarian cystectomies, 1 oophorectomy. 6 myomectomies, 1 hysterotomy,
8 laparotomies, 6 vaginal repairs and 1 ventrisuspension.
RESULTS
One hundred and eighty-one patients were admitted to
the trial. They were suffering from moderate pain following
the operations shown in Table I. The results are presented
in two sections corresponding to the two phases of the
trial:
Phase 1: Glijanan in Suppository Form vs. Omnopon
Injection
A total of 609 dosage records was suitable for analysis,
the principal reason for 'drop-out' being insufficient severity
of pain. Table 11 shows the analysis of mean pain relief
scores following the administration of each trial drug.
Significantly higher pain relief scores were obtained follow-
ing Omnopon injection than following Glifanan suppository
for doses 1, 2, and 3. For dose 4 no significant difference
emerged.
Table III shows the number of extra analgesics required
following the administration of each trial analgesic. Over-
all, 64 doses of extra analgesics were administered follow-
ing Glifanan suppository and 23 such doses following the
In order to preserve the double-blind character of the
study, each active suppository was given with a placebo
injection and each active injection was given with a placebo
suppository. In the second phase each active capsule was
given with a placebo injection, and each active injection
with a placebo capsule. The Glifanan in phase 2 was
prepared in capsule form in order to facilitate the pro-
duction of double-blind material.
In the trial, provision was made for the use of a 'back-
up' analgesic if analgesia was not produced within one
hour, and all such administrations were recorded. Various
'back-up' drugs were used, but pethidine 100 mg was used
for the majority of patients. Effects other than the relief of















"Daie re<:eived: 2 OClOber 1970.
Although Glifanan has been available in South Africa for
two years, no well-controlled clinical evaluations have been
reported in this country. It was therefore decided to con-
duct an investigation into the efficacy of Glifanan using
Omnopon 20 mg as the comparative drug. Chemically,
Glifanan is 7-cWor-4-(0-(2,3-dihydroxy-propoxy-carbonyl)
anilino) quinoline, a synthetic compound related to the
quinoline group of antimalarial drugs. In animal tests it
was found to have an analgesic potency 5 - 10 times greater
than that of aspirin.' Anti-inflammatory and antipyretic
properties were also demonstrated, but these were not as
marked as the analgesic property. Initial clinical evalua-
tions have also demonstrated marked analgesic potency.'·"
TRIAL DESIGN
Pathological pain is acknowledged to be the best yardstick
for the measurement of analgesic effect.'" In particular,
postoperative pain, subjectively assessed, has given accurate
and reproducible results. Excellent patient discernment
between differing degrees of analgesia was obtained.""·"
The investigation reported here involved postoperative
pain in gynaecological and obstetric patients. The trial was
a double-blind cross-over study. The trial medications
were administered 6-hourly and the order of administration
was randomized throughout. The study consisted essen-
tially of two consecutive phases:
Phase 1. During the first 24 hours postoperatively
Glifanan 500 mg in suppository form was compared with
Omnopon 20 mg by injection.
Phase 2. During the subsequent 12 hours Glifanan
200 mg in capsule form was compared with Omnopon
20 mg by injection. Subjective pain assessment was made
at the time of each drug administration and at hourly
intervals for the next 5 hours.
In order to permit statistical evaluation of the results,
pain was classified and scored according to principles
suggested by Keele." The classification and scores were as
follows:




The score at each hourly assessment was subtracted from
the score at the time of administration. The 5 such values
obtained were added to give a pain relief score for each
dose.
TABLE H. A.N"ALYSIS OF MEAN PAIN RELIEF SCORES FOR OMNOPON INJECTIO' AND GllFANAN SUPPOSITORY
Mean pain relief score
Difference
Glifanan Omnopoll between
sUpposiTOry injection means t d·f· Significance
Dose I 3-39 5·86 2·57 4·108 168 s (p<O·OOI)
Dose 2 4·67 5·98 I· 31 2·127 152 s (O·025<p<O·05)
Dose 3 4·52 5·70 I-18 2·638 156 s (O·OO5<p<0{)l)
Dose 4 3-56 4-89 I· 33 1·891 125 nos. (O·05<p<0·1)



























side-effects ID 14 5
Side-effects
_Tausea 3 9 1
Dizziness 2 7 1
Vomiting 2 4 2
Headache 2 2
Others 3* 3t 2t
Total 12 25 6
Table VII shows the number of extra analgesics required
following the administration of each trial analgesic. The
difference is not statistically significant.
'These side-effeclS included itchiness (I), prickly rash (1), sore throat (I)
(probably intubation difficulty).
tThese side-effects included itchiness (2). rash (I).
tThese side-effeclS included sweating (I), mild hypotension (I).
The mean pain relief scores following Omnopon in-
jection and oral Glifanan showed no statistically significant
difference (Table VI).
Trial doses followed by extra analgesics





















side-effects 17 25 26 68
Side-effects
Nausea 14 9 16 39
Vomiting 13 9 7 29
Dizziness 7 10 5 22
Headache 3 2 2 7
Sweating 1 2 2 5
Others 3* 6, 5t 14
Total 41 38 37 116
administration of Omnopon. This difference is statistically
significant (x' = 26'7, 1 dJ., p<O·OOI).
Table IV shows the incidence, type and distribution of
side-effects during phase 1.
'These side-effects included palpitations in 1 patient, rash on arm (1),
abdominal cramps (1).
tThese side-effects included mild hypotension (3), iaundice (1), rash at
injection site (1), pain at injection site (l).
;These side-effects included mild hypotension (1), light-headedness (I),
hiccough (1), rash (1), shivering (1).
Trial doses followed by extra analgesics
Trial doses not followed by extra analgesics
TABLE V. DISTRIBUTION OF ANALYSABLE RECORDS-PHASE 2
Phase 2: Glifanan in Capsule Form vs. Omnopon Injection
One hundred and sixty-two patients were given both trial
drugs. Of these, 85 patients received Glifanan followed by
Omnopon and the remaining 77 Omnopon followed by
Glifanan. A further 3 patients received Glifanan only and
9 Omnopon only.
A total of 246 dosage records was available for analysis
(Table V). Again the principal reason for 'drop-out' was
insufficient severity of pain. There was no significant
difference in the mean initial pain scores of the two treat-
ment groups.
Drugs received
Glifanan followed by Omnopon




















Table VIII shows the incidence, type and distribution
of side-effects during phase 2.
DISCUSSION
The main object of this investigation was the comparative
evaluation of oral Glifanan and Omnopon injection in
order to determine the place of Glifanan in the analgesic
spectrum.
The results obtained indicate that a high level of anal-
gesia is possible with 200 mg of Glifanan by mouth. The
pain relief was found to be comparable to that obtained
from Omnopon injection 20 mg. On the evidence presented
it would appear that Glifanan could be a useful means of
minimizing the therapeutic gap between analgesics of the
aspirin type and the narcotic analgesics.
As postoperative patients were the subject of the study
it was necessary to wait until they could tolerate oral
medication. Glifanan was, however, made available in the
form of suppositories and it was therefore decided to use
the first 24 hours in a second experiment comparing
Glifanan suppositories with Omnopon. Glifanan in this
form was found to be less effective than Omnopon, but
TABLE VI. ANALYSIS OF MEAN PAIN RELIEF SCORES FOR ·OMNOPON INJECTION AND ORAL GLIFANAN
Mean pain relief score
Difference
Omnopon Glifanan between
injection capsules means d·f. Significance
Dose 1 5-80 4·&7 0·93 1·402 132 D.S. (0'1<p<0-2)
Dose 2 5·55 5·07 0-48 0·777 113 D.S. ({)-4<p<6'5)
-
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a considerable degree of analgesia was nevertheless ob-
rained.
In a subsequent investigation elsewhere" the blood levels
obtained following rectal GIifanan were found to be lower
han those obtained following oral GIifanan, and this
could aGcount for the therapeutic difference observed.
It was gratifying to find that the method used was suffi-
ciently sensitive to establish these differences and this
must endorse the findings in the main phase of the trial.
Side-elIects noted throughout were of a minor nature
and it is difficult to draw any conclusions regarding these
since they all occurred within 36 hours of a major opera-
tion.
SUMMARY
A double-blind cross-over technique was used to evaluate the
pain dief obtained postoperatively. i!1 gxnaecological and
obste:ric patIents followlDg the admlillstratlOn of Omnopon
injection, Glifanan suppositories. and Glifanan c.apsules. Pain
was classified hourly by the patient and paID relief scores for
each test administration were calculated and statistically
analysed. Thesc shO\~e<:l n.o statistically signi~cant difference
following Omnopon IllJectlOn 20 mg and Ghfanan capsules
200 mg. Pain relief scores following Omnopon injection 20 mg
were significantly higher than those following Glifanan sup-
positories 500 mg.
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THE ELECTROCARDIOGRAM IN CHRONIC BRONCmTIS AND EMPHYSEMA*
S. ZWI, B.sc., M.B., B.CH. (RAND), M.R.C.P. (LOND.), D. J. KANAREK, M.B., B.CH. (RAND), D.C.H. (R.C.P. & S.),
F.c.P. (SA), A. 1. CROSLEY, M.B., B.CH., (RAND), F.C.P. (SA) AND H. I. GOLDMAN, B.sc. HONS. (RAND),
Respiratory Unit, Department of Medicine, University of the WitlVatersrand and Johannesburg Hospital
There have been a considerable number of reports on the
subject of the electrocardiogram in chronic lung disease.
Generally, the authors have included a variety of lung
diseases, including bronchiectasis and pneumoconiosis,
though the majority of cases have been diagnosed as
chronic bronchitis and emphysema. Some articles included
various lung function tests, but these usually provided
evidence of airway obstruction and we could find no
paper in which the degree of hyperinflation (as deter-
mined by the measurement of lung volumes) was taken
into account. The purpose of this communication was
to study the electrocardiograms of patients suffering from
chronic obstructive airways disease and to relate the
electrocardiogram to the degree of obstruction and of
hyperinflation of the lung. A review of relevant findings
in the literature is included.
l\1ATERIAL AND METHODS
Fifty cases were selected from the file.> of the pulmonary
function laboratory. They all had detailed clinical data,
chest radiographs, a 12- or 13-lead scalar electrocardio-
gram, measurement of the forced expiratory volume in 1
'"'Date received: 3 November 1970.
second (FEV,) and the forced vital capacity (FVC), and
in 34 of these there were also measurements of the sub-
divisions of lung volume. All were White subjects over
the age of 30 years. Most of the cases were outpatients,
but some were convalescing in the wards. Patients were
excluded who had a definite history of paroxysmal attacks
of dyspnoea which could be due to asthma, if there was
any evidence of ischacmic heart disease, pneumoconiosis,
rheumatic heart disease or hypertension, or if any other
major disease was present. The patients, therefore, were
a selected group with chronic obstructive airways disease
due to bronchitis and emphysema.
The forced vital capacity was performed on a Godart
Pulmotest and a Collins spirometer was used for the
closed-circuit helium dilution method for the measure-
ment of lung volumes. The 50 cases in the series with
measurements of FEV,/FVC% and 34 with measurements
of residual volume (RV) were subdivided into the cate-
gories mild, moderate and severe obstruction and hyper-
inflation as indicated in Table I. The predicted value
for residual volume is based on normal subjects studied
in this laboratory.'
The electrocardiograms were analysed for the following
